Phase 2Not yet recruitingPriority 2 · High priorityNCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Plain-language summary
This Phase 2 trial is testing XNW5004 tablets for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XNW5004 tablets (DRUG): XNW5004 will be administered orally as tablets.
- Drugs / treatments
- XNW5004 tablets
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details